Holen Sie sich die Stockscreener-App
113.05
2.07%
2.29
Handel nachbörslich:
110.00
-3.05
-2.70%
Schlusskurs vom Vortag:
$110.76
Offen:
$116.4
24-Stunden-Volumen:
1.60M
Relative Volume:
2.15
Marktkapitalisierung:
$2.87B
Einnahmen:
$302.00K
Nettoeinkommen (Verlust:
$-117.10M
KGV:
-10.16
EPS:
-11.13
Netto-Cashflow:
$-129.13M
1W Leistung:
+10.84%
1M Leistung:
+78.20%
6M Leistung:
+561.50%
1J Leistung:
+974.62%
1-Tages-Spanne:
$110.86
$121.21
1-Wochen-Bereich:
$96.35
$121.21
52-Wochen-Spanne:
$10.14
$121.21
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Firmenname
Cidara Therapeutics Inc
Sektor
Branche
Telefon
858-752-6170
Adresse
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Vergleichen Sie CDTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
113.05 | 2.81B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-12 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-08 | Eingeleitet | Guggenheim | Buy |
| 2024-08-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-09-22 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-07-26 | Eingeleitet | Citigroup | Buy |
| 2017-04-21 | Eingeleitet | Raymond James | Strong Buy |
| 2017-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-04-11 | Fortgesetzt | Wedbush | Outperform |
| 2017-02-22 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-22 | Hochstufung | WBB Securities | Sell → Hold |
| 2016-12-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-09-23 | Herabstufung | WBB Securities | Hold → Sell |
| 2015-10-09 | Hochstufung | WBB Securities | Sell → Hold |
| 2015-05-11 | Eingeleitet | Jefferies | Buy |
| 2015-05-11 | Eingeleitet | Leerink Partners | Outperform |
| 2015-05-11 | Eingeleitet | Needham | Buy |
| 2015-05-11 | Eingeleitet | Wedbush | Outperform |
| 2015-04-23 | Eingeleitet | WBB Securities | Sell |
Alle ansehen
Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten
Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co. - MarketBeat
WBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - MarketBeat
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Benzinga
Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388 - Yahoo Finance
Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00 - MarketBeat
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga
Can machine learning forecast Cidara Therapeutics Inc. recovery2025 Geopolitical Influence & Intraday High Probability Alerts - newser.com
Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright - Investing.com Canada
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - The Manila Times
How to build a dashboard for Cidara Therapeutics Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
JPMorgan Initiates Coverage on Cidara Therapeutics With Overweight Rating, $200 Price Target - MarketScreener
Can Cidara Therapeutics Inc. (20D0) stock reach $200 price target2025 Major Catalysts & Fast Gain Stock Tips - newser.com
What institutional flow reveals about Cidara Therapeutics Inc.Trade Entry Summary & Breakout Confirmation Trade Signals - newser.com
Forecasting Cidara Therapeutics Inc. price range with options data2025 Volatility Report & Stepwise Swing Trade Plans - newser.com
Biotech And Healthcare Stocks Hit 52-Week Highs: Is The Momentum Sustainable? - Nasdaq
Why Cidara Therapeutics Inc. stock could be next big winnerQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Cidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Why Cidara Therapeutics Stock Crushed It Today - sharewise.com
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - Nasdaq
CDTX Surges on FDA's Breakthrough Therapy Designation - GuruFocus
Why Cidara Therapeutics Stock Crushed It Today - The Motley Fool
Cidara Therapeutics Surge: Time to Dive In? - StocksToTrade
FDA grants breakthrough therapy status to Cidara’s influenza drug By Investing.com - Investing.com Nigeria
CDTX Analyst Rating Update: WBB Securities Raises Price Target | - GuruFocus
Cidara Therapeutics stock hits 52-week high at 106.71 USD By Investing.com - Investing.com Nigeria
CDTX Achieves New Heights: What’s Next? - timothysykes.com
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral - Stocktwits
Cidara wins FDA “Breakthrough” status for CD388 - The Pharma Letter
HC Wainwright Maintains Buy Rating on CDTX, Raises Price Target - GuruFocus
HC Wainwright Raises Cidara Therapeutics' Price Target to $150 From $110, Buy Rating Kept - MarketScreener
Cidara Therapeutics stock hits 52-week high at 106.71 USD - Investing.com India
Cidara Therapeutics (CDTX) Gains FDA Breakthrough Designation fo - GuruFocus
Cidara Therapeutics Receives FDA Breakthrough Therapy Designation for CD388 as Prophylactic Against Influenza A and B - Quiver Quantitative
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy - GlobeNewswire
Breakthrough Therapy for CD388 Granted; Cidara Advances Phase 3 ANCHOR Trial Expanded to Older Adults - Stock Titan
What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stock2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
How Cidara Therapeutics Inc. (20D0) stock performs in volatility spikesJuly 2025 Sentiment & Weekly Market Pulse Alerts - newser.com
Is Cidara Therapeutics Inc a good long term investmentDividend Reinvestment Plans & Big Profit Low Investment - earlytimes.in
Cidara Therapeutics (NASDAQ:CDTX) Shares Up 5.5%Time to Buy? - MarketBeat
Cidara announces funding for non-vaccine flu preventive, CD388 - CIDRAP
How Cidara Therapeutics Inc. (20D0) stock reacts to Fed tightening2025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
How buyback programs support Cidara Therapeutics Inc. (20D0) stockCEO Change & Short-Term High Return Ideas - newser.com
Will Cidara Therapeutics Inc. outperform the marketBull Run & Low Drawdown Investment Ideas - newser.com
Biotech Stocks To Research – October 3rd - Defense World
Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring? - ts2.tech
JMP Securities Maintains Cidara Therapeutics (CDTX) Market Outperform Recommendation - Nasdaq
Cidara Therapeutics’ Surprise Surge: What Led the Charge? - timothysykes.com
Biotech Stocks To ResearchOctober 3rd - MarketBeat
Finanzdaten der Cidara Therapeutics Inc-Aktie (CDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cidara Therapeutics Inc-Aktie (CDTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 26 '25 |
Buy |
44.00 |
2,272,727 |
99,999,988 |
3,365,523 |
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):